November 2017 Newsletter



Logicink announces first product to market: Logicink UV

On October 19, at Breakout Lab’s Unboxing event, LogicInk, a pioneer in programmable materials, announced its first product to market: LogicInk UV, a wearable that resembles a temporary tattoo and monitors your UV exposure, signaling when it is time to take action to prevent skin damage.

The company’s first product, LogicInk UV, targets people concerned about radiation from the sun that can cause (1) severe diseases such as skin cancer and (2) the premature aging of the skin (photoaging). LogicInk UV is not powered by electronics. Instead its user interface is programmed with chemistry, alerting users when they have reached a safe daily UV limit determined by medical research on minimal erythemal dose (MED). MED identifies the least amount of UV exposure needed for each skin tone to get a noticeable sunburn.

LogicInk has raised $1M in a pre-seed round from Mission Bay Capital; Peter Thiel’s Breakout Labs, Berkeley Catalyst Fund; Antoine Blondeau, the CEO of; and others. LogicInk is currently raising a seed round.

Logicink is asking anyone interested in the upcoming beta program to sign up now at to stay informed about when and how to try LogicInk UV.

Logicink San Francisco Team (left to right): Kari Workman, Claire LeMaitre, Steven Wrobel, Julie Cushen, Carlos Olguin


Mitokinin is developing a novel class of kinase-targeted neo-substrates for the treatment of neurodegenerative and mitochondrial diseases.

Scribe Biosciences is developing the next generation of high throughput single cell analysis tools for clinical and research applications. The company is based on Printed Droplet Microfluidics (PDM), a technology spun out of the Abate and Gartner labs at UCSF to enable the flexible and programmable handling of single cells with unsurpassed control. Scribe is currently being contracted by DARPA to build a single cell virology platform to enable the study of evolutionary processes in infectious diseases.



Lunch and Learn: November 9, 12:30 – 1:30 PM, Office Hours
Presentations for Investors as Opposed to Partners
Neil Berkley, MBA
West Coast Business Development & Transactions, GlaxoSmithKleinRSVP

Neil Berkley joined GSK in 2014 as part of WWBD’s efforts to expand its presence in the Western half of North America. In this role, Neil supports BD Heads in search and evaluation of West Coast opportunities. In 2016, Neil also became part of the WWBD Transactions team which is responsible for negotiating and structuring deals. Before joining GSK, Neil was Head of Business Development at Cadence Pharmaceuticals, a commercial stage acute care company, where he was part of the team who successfully sold the company to Mallinckrodt for $1.3B in cash. Prior to Cadence Pharmaceuticals, Neil held various roles with a primary focus on business development at Mpex Pharmaceutical, an antibacterial company he co-founded in 2001. During his time at Mpex, Neil helped raise over $100M in venture capital financing and closed multiple business development transactions including an option deal with GSK and the acquisition of Mpex by Aptalis in 2011. Neil also co-founded another San Diego-based biotechnology company, Vaxiion Therapeutics, which is developing a novel therapy for bladder cancer. Prior to his industry experience, Neil worked in several different academic laboratories studying immunology, cardiac virology and microbiology. Neil holds a BS in molecular biology from the University of California, San Diego and an MS in cellular and molecular biology as well as an MBA from San Diego State University.

Neil Berkley will also be offering Office Hours on the same day, November 9, from 9:00 – 12:00 PM. To apply for Office Hours, please contact Linda Eng.


Demo and Happy Hour: November 16, 3:30 – 5:00 PM



TetraScience connects your existing lab instruments to a single online dashboard where you can manage experiments and equipment, plus access data. Easily connect the dots between data, insights, and outcomes.

TetraScience will be on-site to share how they have been helping fast growing biotech companies scale their lab operations through a variety of solutions. Join us for an informal discussion and happy hour with several members of their team.



qb3at953 News

Upcoming Event

  • Capitalizing on New Trends of Chinese Investments in the U.S. and Navigating Legal Issues for Startups in China

    Karen Wong, PhD, Partner Wilson Sonsini Goodrich & Rosati RSVP The rapid growth of the healthcare market in China is fueling many Chinese funds and pharmaceutical companies to invest in healthcare companies in the US and to attract talent to set up companies in China. This presents an unprecedented cross-border environment and new business opportunities for Bay Area entrepreneurs. Please join us for a lively and hands-on discussion with Dr. Karen Wong, a partner of Wilson Sonsini Goodrich & Rosati, to learn about real-life stories, opportunities, and pitfalls in setting up startups with planned growth or commercialization in China. Karen will cover the topics of US-China cross-border deal structures, technology transfer and licensing, fundraising and term-sheet negotiation, and patent filing strategies for both the US and China markets. Dr. Karen Wong has a wealth of experience in life sciences patent preparation and prosecution, technology transfer and licenses, and due-diligence studies in connection with VC financing, M&A, and public offering. Dr. Karen Wong has served as IP counsel to many venture-backed companies in the US and in China, and has worked on numerous major cross-border transactions, strategic alliance transactions, acquisitions, spin-outs, and IPOs. Karen is fluent in Mandarin, Cantonese, and Sichuan dialect.


953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287

Sign-Up for our Newsletter